Bridge Bio Eyes Faster Pipeline Progress Through New Funds, Model
This article was originally published in PharmAsia News
Executive Summary
A Series A funding for South Korean bioventure Bridge Biotherapeutics may encourage creation of “no research, development only” bioventures and early investments in the biotech sector.
You may also be interested in...
INTERVIEW: Bridge Chief On Pursuing NRDO, Global Ambitions
Bridge Biotherapeutics is off to a great start with its recent successful Series A funding, raising the largest amount so far for a South Korean bioventure. The company’s CEO talks to Scrip about where the company is heading including plans for its first-in-class inflammatory bowel disease candidate and further financings.
A Peek Into Korean Bioventures’ Success Factors, Challenges
Amid a boom in IPOs and valuations, experts at a recent forum in Seoul took a look at some of the success factors and challenges behind the rapid growth of South Korea’s bioventure sector.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.